Home > Healthcare > Pharmaceuticals > Pharma Manufacturing > Recombinant Protein Therapeutics CDMO Market

Recombinant Protein Therapeutics CDMO Market Size

Report ID: GMI8819
Published Date: Apr 2024
Report Format: PDF

Download Free Sample

Recombinant Protein Therapeutics CDMO Market Size

Recombinant Protein Therapeutics CDMO Market size was USD 21 billion in 2023 and is set to register growth at 14% to reach USD 67.6 billion by 2032. Increasing prevalence of chronic diseases such as cancer, diabetes, and autoimmune disorders has led to a growing demand for effective protein-based treatments. This has resulted in a greater need for CDMOs with expertise in producing high-quality recombinant proteins, thereby enhancing the market growth.

To get key market trends

Download Free Sample

For instance, the World Health Organization reported 20 million cancer cases worldwide in 2022, with projections of over 35 million new cases by 2050. This increasing burden of chronic diseases increases the demand for effective recombinant protein-based treatments, thereby contributing to the market's growth. Moreover, the rise in outsourcing of drug development and manufacturing activities by pharmaceutical and biotechnology companies is boosting the demand for CDMOs specializing in recombinant proteins. Furthermore, the growing pipeline of biologics, including recombinant protein therapeutics, is expected to fuel the demand for CDMO services in this market.

Recombinant Protein Therapeutics CDMO Market Report Attributes
Report Attribute	Details
Base Year:	2023
Recombinant Protein Therapeutics CDMO Market Size in 2023:	USD 21 Billion
Forecast Period:	2024 - 2032
Forecast Period 2024 - 2032 CAGR:	14%
2032 Value Projection:	USD 67.6 Billion
Historical Data for:	2021 - 2023
No. of Pages:	180
Tables, Charts & Figures:	317
Segments covered:	Type, Source, Therapeutic Area, Service Type, End-user, and Region
Growth Drivers:	Increasing demand for biologics Rising adoption of CDMOs for outsourcing manufacturing activities Rising investments in R&D
Pitfalls & Challenges:	High cost of manufacturing Quality control challenges

Learn more about the key segments shaping this market

Download Free Sample

A recombinant protein therapeutics contract development and manufacturing organization (CDMO) is a specialized service provider that offers contract development and manufacturing services for recombinant protein-based therapeutics. Recombinant protein therapeutics are a class of biologic drugs produced by genetically engineering living cells to express proteins with therapeutic properties. CDMO’s provide a range of services tailored to support the development and manufacturing of these biologic drugs on behalf of pharmaceutical and biotechnology companies.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Recombinant protein therapeutics CDMO market size was USD 21 billion in 2023 and is expected to register 14% CAGR from 2024-2032 owing to Increasing prevalence of chronic diseases such as cancer, diabetes, and autoimmune disorders worldwide.

Recombinant protein therapeutics CDMO industry from the mammalian segment recorded over 61.5% share in 2023 and is expected to register an appreciable CAGR from 2024-2032 due to being preferred to produce complex protein therapeutics such as cytokines and growth factors.

North America recombinant protein therapeutics CDMO industry reached USD 8.5 billion in 2023 and is expected to register a commendable CAGR from 2024-2032 due to access to advanced technologies, state-of-the-art infrastructure, and cutting-edge research capabilities in the region.

Batavia Biosciences B.V., BIOVIAN, Catalent, Inc, Curia Global, Inc., Enzene Biosciences Ltd, FUJIFILM Diosynth Biotechnologies, HALIX B.V., Lonza, Richter-Helm BioLogics, and WuXi Biologics, are some of the major Recombinant Protein Therapeutics CDMO companies worldwide.